Peter Pitts Discusses Expedited Reviews and the Current State of Drug Development

Peter Pitts:
Regardless of what you want to call it, whether it’s expedited review or special protocols, limited use medicines, the theory is, “How can the FDA help bring important therapies to the market faster?” And, there are a lot of pieces to that puzzle.

At the end of the day, the agency still has to meet with the sponsor, who still has to have data. They have to meet and decide how to move forward.

There are two issues that also have to come into this conversation:
  1. The patient voice
  2. Benefit / risk profile
Those are two things that really are not usually discussed. Generally speaking, in this type of conversation what comes about in the discussion is time. How quickly can something happen? Obviously faster is better than slower, but you don’t want to ever sacrifice proper review.
 
Sign Up for Our Email Newsletter

RECENT NEWS

Principles for PBM Reform and Patient Centered Prescription Drug Benefits

Principles for PBM Reform and Patient Centered Prescription Drug Benefits

CMPI & NCPA Forum Panel Two discussion: Principles for PBM Reform and Patient Centered Prescription Drug Benefits...  Read more

Keynote Speech: A. Mark Fendrick, M.D.

Keynote Speech: A. Mark Fendrick, M.D.

CMPI & NCPA Forum Keynote Speech: Mark Fendrick, M.D., Director, Center for Value Based Insurance Design, University of M...  Read more

How PBMs Affect Access and Affordability

How PBMs Affect Access and Affordability

CMPI & NCPA Forum Panel One discussion: How PBMs Affect Access and Affordability...  Read more

DRUGWONKS BLOG